These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 37838479

  • 1. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
    Sukwa N, Mubanga C, Hatyoka LM, Chilyabanyama ON, Chibuye M, Mundia S, Munyinda M, Kamuti E, Siyambango M, Badiozzaman S, Bosomprah S, Carlin N, Kaim J, Sjöstrand B, Simuyandi M, Chilengi R, Svennerholm AM.
    Vaccine; 2023 Nov 02; 41(46):6884-6894. PubMed ID: 37838479
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
    Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A, Wiklund G, Kaim J, Löfstrand M, Carlin N, Bourgeois AL, Maier N, Fix A, Wierzba T, Walker RI, Svennerholm AM.
    Lancet Infect Dis; 2020 Feb 02; 20(2):208-219. PubMed ID: 31757774
    [Abstract] [Full Text] [Related]

  • 3. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.
    Vaccine; 2013 May 07; 31(20):2457-64. PubMed ID: 23541621
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
    Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A.
    Vaccine; 2019 Sep 03; 37(37):5645-5656. PubMed ID: 30473185
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
    Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM.
    Vaccine; 2014 Dec 12; 32(52):7077-84. PubMed ID: 25444830
    [Abstract] [Full Text] [Related]

  • 6. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
    Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM.
    Vaccine; 2013 Feb 06; 31(8):1163-70. PubMed ID: 23306362
    [Abstract] [Full Text] [Related]

  • 7. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
    Bernstein DI, Pasetti MF, Brady R, Buskirk AD, Wahid R, Dickey M, Cohen M, Baughman H, El-Khorazaty J, Maier N, Sztein MB, Baqar S, Bourgeois AL.
    Vaccine; 2019 Jan 21; 37(4):602-611. PubMed ID: 30563789
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.
    El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH.
    Clin Vaccine Immunol; 2013 Nov 21; 20(11):1764-70. PubMed ID: 24049109
    [Abstract] [Full Text] [Related]

  • 9. Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenicEscherichia coli (ETEC) vaccine ETVAX.
    Leach S, Lundgren A, Carlin N, Löfstrand M, Svennerholm AM.
    Vaccine; 2017 Jul 13; 35(32):3966-3973. PubMed ID: 28625524
    [Abstract] [Full Text] [Related]

  • 10. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
    Svennerholm AM, Qadri F, Lundgren A, Kaim J, Rahman Bhuiyan T, Akhtar M, Maier N, Louis Bourgeois A, Walker RI.
    Vaccine; 2022 Jan 21; 40(2):380-389. PubMed ID: 34772542
    [Abstract] [Full Text] [Related]

  • 11. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
    Byrd W, Boedeker EC.
    Vet Immunol Immunopathol; 2013 Mar 15; 152(1-2):57-67. PubMed ID: 23122616
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli.
    Lee T, Gutiérrez RL, Maciel M, Poole S, Testa KJ, Trop S, Duplessis C, Lane A, Riddle MS, Hamer M, Alcala A, Prouty M, Maier N, Erdem R, Louis Bourgeois A, Porter CK.
    Vaccine; 2021 Sep 15; 39(39):5548-5556. PubMed ID: 34419306
    [Abstract] [Full Text] [Related]

  • 13. Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine.
    Lundgren A, Jertborn M, Svennerholm AM.
    Vaccine; 2016 Jun 08; 34(27):3132-3140. PubMed ID: 27133878
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of ETVAX®, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West Africa.
    Kantele A, Riekkinen M, Jokiranta TS, Pakkanen SH, Pietilä JP, Patjas A, Eriksson M, Khawaja T, Klemets P, Marttinen K, Siikamäki H, Lundgren A, Holmgren J, Lissmats A, Carlin N, Svennerholm AM.
    J Travel Med; 2023 Nov 18; 30(7):. PubMed ID: 37099803
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.
    Luo Q, Vickers TJ, Fleckenstein JM.
    Clin Vaccine Immunol; 2016 Jul 18; 23(7):628-37. PubMed ID: 27226279
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity of recombinant Lactobacillus casei-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic Escherichia coli as an oral adjuvant in mice.
    Yu M, Qi R, Chen C, Yin J, Ma S, Shi W, Wu Y, Ge J, Jiang Y, Tang L, Xu Y, Li Y.
    J Appl Microbiol; 2017 Feb 18; 122(2):506-515. PubMed ID: 27860074
    [Abstract] [Full Text] [Related]

  • 17. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
    McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA.
    Infect Immun; 2006 Feb 18; 74(2):994-1000. PubMed ID: 16428745
    [Abstract] [Full Text] [Related]

  • 18. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.
    McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM.
    Vaccine; 2007 May 04; 25(18):3684-91. PubMed ID: 17313998
    [Abstract] [Full Text] [Related]

  • 19. Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.
    Maciel M, Bauer D, Baudier RL, Bitoun J, Clements JD, Poole ST, Smith MA, Kaminski RW, Savarino SJ, Norton EB.
    Infect Immun; 2019 Nov 04; 87(11):. PubMed ID: 31427449
    [Abstract] [Full Text] [Related]

  • 20. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.
    Lapa JA, Sincock SA, Ananthakrishnan M, Porter CK, Cassels FJ, Brinkley C, Hall ER, van Hamont J, Gramling JD, Carpenter CM, Baqar S, Tribble DR.
    Clin Vaccine Immunol; 2008 Aug 04; 15(8):1222-8. PubMed ID: 18579693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.